SciBase Secures Financial Backing for Ongoing Rights Issue Amid Future Investments#Sweden#Stockholm#SciBase#Rights_Issue#Bergs_Securities
SciBase Secures Financial Backing for Ongoing Rights Issue Amid Future Investments
SciBase Holding AB has confirmed a significant guarantee commitment supporting its rights issue, aimed at strengthening its financial position for future growth.
third-news.com
September 25, 2026 at 10:02 AM
SciBase Secures Financial Backing for Ongoing Rights Issue Amid Future Investments#Sweden#Stockholm#SciBase#Rights_Issue#Bergs_Securities
SciBase Secures Financial Backing Through Guarantee Commitment for Rights Issue#Sweden#Stockholm#SciBase#Rights_Issue#Bergs_Securities
SciBase Secures Financial Backing Through Guarantee Commitment for Rights Issue
SciBase Holding AB has successfully secured a significant guarantee commitment from Bergs Securities, ensuring full financial backing for its current rights issue.
third-news.com
September 25, 2026 at 7:37 AM
SciBase Secures Financial Backing Through Guarantee Commitment for Rights Issue#Sweden#Stockholm#SciBase#Rights_Issue#Bergs_Securities
ME Research UK:
A paper by independent researchers Mark Vink and Alexandra Vink-Niese confirms the conclusion by NICE that CBT is not an effective treatment for ME/CFS, & highlights the need for researchers to be open and transparent in their research.
Read more: bit.ly/3O4qRt4
#MEcfs #CFS #PwME
A paper by independent researchers Mark Vink and Alexandra Vink-Niese confirms the conclusion by NICE that CBT is not an effective treatment for ME/CFS, & highlights the need for researchers to be open and transparent in their research.
Read more: bit.ly/3O4qRt4
#MEcfs #CFS #PwME
November 19, 2024 at 5:02 PM
ME Research UK:
A paper by independent researchers Mark Vink and Alexandra Vink-Niese confirms the conclusion by NICE that CBT is not an effective treatment for ME/CFS, & highlights the need for researchers to be open and transparent in their research.
Read more: bit.ly/3O4qRt4
#MEcfs #CFS #PwME
A paper by independent researchers Mark Vink and Alexandra Vink-Niese confirms the conclusion by NICE that CBT is not an effective treatment for ME/CFS, & highlights the need for researchers to be open and transparent in their research.
Read more: bit.ly/3O4qRt4
#MEcfs #CFS #PwME
There is no better way of expressing how left behind we are as patients: the latest research paper is by a bed-bound patient confirming that previously debunked science is still shitty science. #mecfs #peME #junkscience #greatestMEdicalscandal #johnvsjonvsME
www.scibasejournals.org/neurology/10...
www.scibasejournals.org/neurology/10...
November 15, 2024 at 1:43 AM
There is no better way of expressing how left behind we are as patients: the latest research paper is by a bed-bound patient confirming that previously debunked science is still shitty science. #mecfs #peME #junkscience #greatestMEdicalscandal #johnvsjonvsME
www.scibasejournals.org/neurology/10...
www.scibasejournals.org/neurology/10...
SciBase Issues New Information Document for Share Rights Issue, Aims for SEK 58 Million#Sweden#Stockholm#Nevisense#SciBase#Rights_Issue
SciBase Issues New Information Document for Share Rights Issue, Aims for SEK 58 Million
SciBase Holding AB has announced an information document concerning its rights issue aiming to raise approximately SEK 58 million. Key details are provided in this publication.
third-news.com
September 14, 2026 at 2:48 PM
SciBase Issues New Information Document for Share Rights Issue, Aims for SEK 58 Million#Sweden#Stockholm#Nevisense#SciBase#Rights_Issue
Leadership Transition at SciBase: Pia Renaudin Steps Down as CEO#Sweden#Stockholm#Nevisense#SciBase#Pia_Renaudin
Leadership Transition at SciBase: Pia Renaudin Steps Down as CEO
SciBase Holding AB announces the departure of CEO Pia Renaudin and reaffirms commitment to its strategic goals in dermatology.
third-news.com
July 28, 2026 at 7:24 AM
Leadership Transition at SciBase: Pia Renaudin Steps Down as CEO#Sweden#Stockholm#Nevisense#SciBase#Pia_Renaudin
SciBase reaches milestone with over 300,000 patients tested with Nevisense
www.viv-media.com/infozx-37102...
www.viv-media.com/infozx-37102...
SciBase reaches milestone with over 300,000 patients tested with Nevisense
www.viv-media.com
May 27, 2025 at 1:20 PM
SciBase reaches milestone with over 300,000 patients tested with Nevisense
www.viv-media.com/infozx-37102...
www.viv-media.com/infozx-37102...
SciBase Reports Significant Growth in Q1 2026 Despite Financial Losses and Challenges#Sweden#Stockholm#dermatology#Nevisense#SciBase
SciBase Reports Significant Growth in Q1 2026 Despite Financial Losses and Challenges
In Q1 2026, SciBase shows impressive sales growth of 61% year-on-year, facing losses and challenges while expanding its dermatological offerings.
third-news.com
May 7, 2026 at 9:16 AM
SciBase Reports Significant Growth in Q1 2026 Despite Financial Losses and Challenges#Sweden#Stockholm#dermatology#Nevisense#SciBase
SciBase Launches Groundbreaking Study for Early Flare Prediction in Atopic Dermatitis Using AI Technology#Sweden#Stockholm#Atopic_Dermatitis#Nevisense#SciBase
SciBase Launches Groundbreaking Study for Early Flare Prediction in Atopic Dermatitis Using AI Technology
SciBase has enrolled its first patient in a pioneering study aimed at predicting flares in atopic dermatitis using advanced AI techniques. This study marks a crucial step toward proactive skincare.
third-news.com
June 10, 2026 at 7:10 AM
SciBase Launches Groundbreaking Study for Early Flare Prediction in Atopic Dermatitis Using AI Technology#Sweden#Stockholm#Atopic_Dermatitis#Nevisense#SciBase
SciBase Reports Significant Growth in First Quarter of 2026 Amid Strategic Developments#Sweden#Stockholm#dermatology#Nevisense#SciBase
SciBase Reports Significant Growth in First Quarter of 2026 Amid Strategic Developments
SciBase has shown impressive growth metrics in Q1 2026 with a 61% increase in net sales compared to the previous year and key advancements in product offerings.
third-news.com
May 7, 2026 at 7:12 AM
SciBase Reports Significant Growth in First Quarter of 2026 Amid Strategic Developments#Sweden#Stockholm#dermatology#Nevisense#SciBase
Insights from SciBase Holding AB's 2026 Annual General Meeting#Sweden#AGM#Stockholm#SciBase_Holding#Nevisense
Insights from SciBase Holding AB's 2026 Annual General Meeting
The annual general meeting of SciBase Holding AB showcased key decisions including financial reports, board elections, and stock options.
third-news.com
May 19, 2026 at 10:25 AM
Insights from SciBase Holding AB's 2026 Annual General Meeting#Sweden#AGM#Stockholm#SciBase_Holding#Nevisense
Confirmed: The Conclusion by UK NICE that CBT is NOT an Effective Treatment for ME/CFS; Re-Analysis of a Systematic Review M. Vink A. Vink Niese #ME/CFS #PwME
www.scibasejournals.org/neurology/10...
www.scibasejournals.org/neurology/10...
![participated in seven of the eight included RCTs in the system-
SciBase Neurology
Control groups should be properly matched and designed
Finally, in March 2009, "the World Association of Medical
Editors revised its policy on competing interests to emphasize nonfinancial competing interests, including academic commit-
•Studies should not use a wait list, no treatment or usua care, or other control groups where patients do not re-ceive a control treatment with the same frequency, du-
ments, personal relationships, political or religious beliefs and institutional affiliations" (p. 11 (88)). As a consequence, the
study as people in the treatment group (36-40);
Canadien mealcal Associaton sournal changed is pollcy ac-
cordingly, and in an editorial it emphasized that ull disclosure• Patients and/or carers should be involved in the design (of competing interest] is particularly important for authors of
commentaries, editorials and review articles (italic by us). Be- • Definitions of recovery should be based on objective out-cause such articles often offer explicit guidance, readers ex-
comes;
pect a stronger guarantee of integrity* (p. 12 [88)). Why the
researchers of the systematic review ignored all that, is unclear. • Non-blinded studies that deem treatments to be effec-
tive, based on subjective outcomes, should be rejected
Checklist of recommendations on how to design and con-
for publication;
duct treatment studies for ME/CFS
• Misdiagnosed patients should be removed from a study
There are no effective treatments for post infectious diseases
and its analysis;
like ME/CFS and long Covid because the medical profession has
been psychologising those diseases for decades. If we had taken • Future trials are particularly needed for individuals with
severe and very severe ME/CFS because they are devold
had effective pharmacological treatments for the estimated 400
of any medical care, despite being severely ill;
million people with long Covid (89) and the medical professio…](https://cdn.bsky.app/img/feed_thumbnail/plain/did:plc:mpf7s65cdaxc6xpkyzttwuxt/bafkreigdqj5rl2jz55ggcnhhhd2dj5ghzm3qdf4otyx2cunomxmkweou4a)
February 6, 2025 at 9:15 PM
Confirmed: The Conclusion by UK NICE that CBT is NOT an Effective Treatment for ME/CFS; Re-Analysis of a Systematic Review M. Vink A. Vink Niese #ME/CFS #PwME
www.scibasejournals.org/neurology/10...
www.scibasejournals.org/neurology/10...
New Study on Early Flare Prediction in Atopic Dermatitis Begins with Patient Enrollment#Sweden#Stockholm#Atopic_Dermatitis#SciBase#Castle_Biosciences
New Study on Early Flare Prediction in Atopic Dermatitis Begins with Patient Enrollment
SciBase and Castle Biosciences initiate a groundbreaking study to predict flares in atopic dermatitis, enhancing patient care.
third-news.com
June 10, 2026 at 7:20 AM
New Study on Early Flare Prediction in Atopic Dermatitis Begins with Patient Enrollment#Sweden#Stockholm#Atopic_Dermatitis#SciBase#Castle_Biosciences
Mayo Clinic Launches Pilot Program to Test AI Tool Nevisense for Skin Cancer Detection#USA#Rochester#Nevisense#SciBase#Mayo_Clinic
Mayo Clinic Launches Pilot Program to Test AI Tool Nevisense for Skin Cancer Detection
The Mayo Clinic is set to collaborate with SciBase to evaluate Nevisense, an AI-driven device aimed at early melanoma detection, enhancing patient care.
third-news.com
January 3, 2025 at 7:20 AM
Mayo Clinic Launches Pilot Program to Test AI Tool Nevisense for Skin Cancer Detection#USA#Rochester#Nevisense#SciBase#Mayo_Clinic
SciBase's Board Approves Record Date for Upcoming Reverse Share Split#Sweden#AI_Technology#Stockholm#Nevisense#SciBase
SciBase's Board Approves Record Date for Upcoming Reverse Share Split
SciBase Holding AB has announced a record date for its reverse share split, consolidating shares to enhance market performance. Learn about the key details and timetable here.
third-news.com
May 28, 2026 at 7:04 PM
SciBase's Board Approves Record Date for Upcoming Reverse Share Split#Sweden#AI_Technology#Stockholm#Nevisense#SciBase
Thanks for sharing. Looking through your tool list, you might like scibase for research, and maybe simtheory for access to new models and ways of working with the
December 31, 2024 at 9:10 AM
Thanks for sharing. Looking through your tool list, you might like scibase for research, and maybe simtheory for access to new models and ways of working with the
New Study Reveals Nevisense's Promise in Predicting Atopic Dermatitis in Infants#Sweden#Stockholm#Atopic_Dermatitis#Nevisense#SciBase
New Study Reveals Nevisense's Promise in Predicting Atopic Dermatitis in Infants
A recent study demonstrates the potential of Nevisense technology in identifying infants at risk of developing atopic dermatitis, paving the way for early intervention strategies.
third-news.com
June 9, 2026 at 2:19 PM
New Study Reveals Nevisense's Promise in Predicting Atopic Dermatitis in Infants#Sweden#Stockholm#Atopic_Dermatitis#Nevisense#SciBase
Nevisense Technology Reveals Skin Damage From Common Cleaners in New Study#Sweden#Stockholm#Nevisense#SciBase#Skin_Barrier
Nevisense Technology Reveals Skin Damage From Common Cleaners in New Study
A recent study highlights how Nevisense technology can identify skin barrier disruptions caused by household cleaning products. The findings indicate potential recovery methods.
third-news.com
May 28, 2026 at 6:24 AM
Nevisense Technology Reveals Skin Damage From Common Cleaners in New Study#Sweden#Stockholm#Nevisense#SciBase#Skin_Barrier
SciBase Updates Trading Dates for Subscription Rights and Paid Shares on Nasdaq#Sweden#NASDAQ#Stockholm#SciBase#Rights_Issue
SciBase Updates Trading Dates for Subscription Rights and Paid Shares on Nasdaq
SciBase Holding AB announces a change in the first trading day for subscription rights and BTA on Nasdaq. Key details of the rights issue are provided within.
third-news.com
September 15, 2026 at 10:11 AM
SciBase Updates Trading Dates for Subscription Rights and Paid Shares on Nasdaq#Sweden#NASDAQ#Stockholm#SciBase#Rights_Issue
SciBase befinner sig i en expansiv fas med kraftig tillväxt inom melanomdiagnostik i USA och nya möjligheter inom andra hudsjukdomar. Cäxande samarbete med Castle Biosciences. Potentiellt viktigt reimbursement-besked i USA. Gör företrädesemission om 58 Mkr. [sponsrad] nyemissioner.se/nyheter/scib...
SciBase stärker positionen inom dermatologi med USA i fokus
SciBase är ett medicintekniskt bolag som utvecklar och kommersialiserar lösningar för tidig upptäckt och prevention inom dermatologi. Med Nevisense, en plattform som kombinerar AI och EIS-teknologi, h...
nyemissioner.se
September 15, 2026 at 1:15 PM
SciBase befinner sig i en expansiv fas med kraftig tillväxt inom melanomdiagnostik i USA och nya möjligheter inom andra hudsjukdomar. Cäxande samarbete med Castle Biosciences. Potentiellt viktigt reimbursement-besked i USA. Gör företrädesemission om 58 Mkr. [sponsrad] nyemissioner.se/nyheter/scib...
SciBase Strengthens Partnership with Castle Biosciences Through New Order and Clinical Studies#Sweden#Stockholm#SciBase#Castle_Biosciences#Nevisense_Go
SciBase Strengthens Partnership with Castle Biosciences Through New Order and Clinical Studies
SciBase has received a new order from Castle Biosciences to expedite their current clinical study while preparing for a second one, enhancing patient care.
third-news.com
September 8, 2026 at 1:59 PM
SciBase Strengthens Partnership with Castle Biosciences Through New Order and Clinical Studies#Sweden#Stockholm#SciBase#Castle_Biosciences#Nevisense_Go
SciBase Strengthens Partnership with Castle Biosciences Through New Order#Sweden#Stockholm#SciBase#Castle_Biosciences#Nevisense_Go
SciBase Strengthens Partnership with Castle Biosciences Through New Order
SciBase has announced a new order from Castle Biosciences, enhancing their collaboration in dermatological research and technology advancements.
third-news.com
September 8, 2026 at 1:46 PM
SciBase Strengthens Partnership with Castle Biosciences Through New Order#Sweden#Stockholm#SciBase#Castle_Biosciences#Nevisense_Go
SciBase har erhållit ytterligare en order från Castle avseende den bärbara Nevisense Go-pennan och elektroder, till ett värde om ca 0,6 MUSD, motsvarande ca 5 MSEK.
analystgroup.se/bolag/scibas...
analystgroup.se/bolag/scibas...
Kommentar på SciBase uppföljningsorder från Castle Biosciences om ca 5 MSEK | SciBase Holding | Analyst Group
Analytikerkommentar om SciBase Holding från Analyst Group.
analystgroup.se
September 8, 2026 at 2:39 PM
SciBase har erhållit ytterligare en order från Castle avseende den bärbara Nevisense Go-pennan och elektroder, till ett värde om ca 0,6 MUSD, motsvarande ca 5 MSEK.
analystgroup.se/bolag/scibas...
analystgroup.se/bolag/scibas...
SciBase Strengthens Collaboration with Castle Biosciences Through Additional Order#Sweden#Stockholm#Nevisense#SciBase#Castle_Biosciences
SciBase Strengthens Collaboration with Castle Biosciences Through Additional Order
SciBase has announced a significant advancement in its collaboration with Castle Biosciences, receiving an additional order aimed at speeding up a clinical study and preparing for a follow-up study.
third-news.com
September 8, 2026 at 1:51 PM
SciBase Strengthens Collaboration with Castle Biosciences Through Additional Order#Sweden#Stockholm#Nevisense#SciBase#Castle_Biosciences
Veckans spaningar från emissionsmarknaden. Klaria meddelade i veckan en större företrädesemission där garantin ännu inte är på plats, Scibase överraskade med ytterligare en emission, några mindre både positiva och negativa händelser och två IPO:s. nyemissioner.se/nyheter/veck...
nyemissioner.se
September 5, 2026 at 9:55 AM
Veckans spaningar från emissionsmarknaden. Klaria meddelade i veckan en större företrädesemission där garantin ännu inte är på plats, Scibase överraskade med ytterligare en emission, några mindre både positiva och negativa händelser och två IPO:s. nyemissioner.se/nyheter/veck...